A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Sinotau Pharmaceutical Group · Neuroendocrine Tumors
Phase 3
Active, not recruiting
196
2025-09
Industry sponsor intelligence
Sinotau Pharmaceutical GroupClinical Pipeline.
Lead-sponsor view of Sinotau Pharmaceutical Group's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 1
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 196
Pipeline overview
Programs by phase and activity.
Velocity
Sinotau Pharmaceutical Group trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Octreotide → | 1 | 0 | 0 | 1 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Sinotau Pharmaceutical Group studies.
This page groups studies where Sinotau Pharmaceutical Group is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates